{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Abbreviation', 'Definition', 'qW', 'Once per week', 'SAE', 'Serious adverse event', 'SAP', 'Statistical analysis plan', 'SST', 'Serum separator tube', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'T1/2', 'Terminal phase elimination half-life', 'Tmax', 'Time to observed maximum concentration', 'TAO', 'Thyroid-associated ophthalmopathy', 'TEAE', 'Treatment-emergent adverse event', 'TED', 'Thyroid eye disease', 'TSH', 'Thyroid stimulating hormone', 'TSHR', 'Thyroid-stimulating-hormone receptor', 'ULN', 'Upper limit of normal', 'VF subscale', 'Visual functioning subscale of GO-QoL', 'Vss', 'Volume of distribution at steady-state', 'WHODrug', 'World Health Organization Drug Dictionary', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 46 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '5', 'ETHICS', '5.1', 'Institutional Review Board/Independent Ethics Committee', 'The Principal Investigator (Investigator), the Sponsor and/or Contract Research Organization', '(CRO) authorized by the Sponsor will submit this protocol, any protocol modifications, and the', 'Informed Consent Form (ICF) and all applicable study documentation to be used in this study to', 'the appropriate Institutional Review Board (IRB) or Independent Ethics Committee (IEC) for', 'review and approval/favorable opinion. A letter confirming the IRB/IEC approval/favorable', 'opinion of the protocol the subject ICF and applicable study documentation, a list of the IRB/IEC', 'members involved in the vote as well as a statement that the IRB/IEC is organized and operates', 'according to Good Clinical Practice (GCP) and the applicable laws and regulations, must be', 'forwarded to the Sponsor or its designee prior to the enrollment of subjects into the study. A', 'copy of the approved ICF will also be forwarded to the Sponsor or its designee. Appropriate', 'reports on the progress of the study will be made to the IRB/IEC and the Sponsor or its designee', 'by the Investigator in accordance with applicable governmental regulations and in agreement', 'with the policy established by the Sponsor.', '5.2 Ethical Conduct of the Study', 'The Investigators will ensure that this study is conducted in a manner that fully conforms with', 'the principles of the \"Declaration of Helsinki\" or with the laws and regulations of the country in', 'which the research is conducted, whichever affords the greater protection to the individual. The', 'study must fully adhere to the principles outlined in \"Guideline for Good Clinical Practice\"', 'International Conference of Harmonization (ICH) Tripartite Guideline or with local law if it', 'affords greater protection to the subject. For studies conducted in the European Union/European', 'Economic Area (EU/EEA) countries, the Investigator will ensure compliance with the EU', 'Clinical Trial Directive [2001/20/EC]. For studies conducted in the USA or under US', 'Investigational New Drug (IND), the Investigator will additionally ensure adherence to the basic', 'principles of \"Good Clinical Practice\" as outlined in the current version of 21 Code of Federal', 'Regulations (CFR), subchapter D, part 312, \"Responsibilities of Sponsors and Investigators\",', 'part 50, \"Protection of Human Subjects\", and part 56, \"Institutional Review Boards\".', 'In other countries where a \"Guideline for Good Clinical Practice\" exists, the Sponsor and the', 'Investigators will strictly ensure adherence to the stated provisions.', '5.3 Subject Information and Consent', 'It is the responsibility of the Investigator, or a person designated by the Investigator (if', 'acceptable by local regulations), to obtain signed informed consent from each subject prior to', 'participating in this study after adequate explanation of the aims, methods, anticipated benefits,', 'and potential hazards of the study.', 'The Investigator or designee must also explain that the subjects are completely free to refuse to', 'enter the study or to withdraw from it at any time, for any reason.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 47 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'The ICF and any other written information provided to subjects will be revised whenever', \"important new information becomes available that may be relevant to the subject's consent, or\", 'there is an amendment to the protocol that necessitates a change to the content of the subject', 'information and/or the written ICF. The Investigator will inform the subject of changes in a', 'timely manner and will ask the subject to confirm his/her participation in the study by signing the', \"revised ICF. Any revised written ICF and written information must receive the IRB/IEC's\", 'approval/favorable opinion in advance of use.', \"All signed ICFs are to remain in the Investigator's site file or, if locally required, in the subjects'\", 'notes/files of the medical institution.', 'The electronic case report forms (eCRFs) for this study contain a section for documenting all', 'subject informed consents, and this must be completed appropriately. If new safety information', 'results in significant changes in the risk/benefit assessment, the consent form should be reviewed', 'and updated if necessary. All subjects (including those already being treated) should be informed', 'of the new information, given a copy of the revised form and give their consent to continue in the', 'study.', '5.4', 'Compensation for Health Damage of Subjects/Insurance', 'The Sponsor maintains clinical trial insurance coverage for this study in accordance with the', 'laws and regulations of the country in which the study is performed.', '5.5 Confidentiality', 'All records identifying the subject will be kept confidential and, to the extent permitted by the', 'applicable laws and/or regulations, will not be made publicly available.', 'Subject names will not be supplied to the Sponsor. Only the subject number will be recorded in', 'the eCRF, and if the subject name appears on any other document, it must be obliterated before a', 'copy of the document is supplied to the Sponsor. Study findings stored on a computer will be', 'stored in accordance with local data protection laws. As part of the informed consent process, the', 'subjects will be informed in writing that representatives of the Sponsor, IRB/IEC, or regulatory', 'authorities may inspect their medical records to verify the information collected, and that all', 'personal information made available for inspection will be handled in strictest confidence and in', 'accordance with local data protection laws.', \"If the results of the study are published, the subject's identity will remain confidential.\", 'The Investigator will maintain a list to enable subjects to be identified.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 48 of 118']\n\n###\n\n", "completion": "END"}